Copley Scientific launches space saving flow control tech for DPI testing

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Dry powder inhalers, Dry powder inhaler

Copley launches space saving flow control tech
Copley launches space saving flow control tech
Copley Scientific expects the new version of its flow rate control technology for dry powder inhaler (DPI) testing to be in demand among both generic drug firms and pharmaceutical innovators.

The Nottingham, UK-based firm launched the new tech - the TPK-R - last week, explaining that its inlets and outlets have been positioned to match those of its aerodynamic particle size distribution (APSD) device – the Next Generation Impactor (NGI) - which means it takes up less space than the older TPK system when the two machines are connected during DPI testing.

A Copley spokeswoman told that: “The TPK predates the NGI and is also used with the other cascade impactor in routine use for this application – The Andersen Cascade Impactor.

Both the ACI and NGI remain in use and are likely to do so for the foreseeable future. There is now an optimal TPK design for each. Within OINDP [Orally Inhaled and Nasal Drug Products] labs the TPK is pretty much a standard so the new introduction will be welcomed by those looking for a more streamlined set-up for their NGI work.

Critical flow rate during testing is critical

Being able to assess particle dynamics is critical to understanding the performance of dry powder inhalers and such data are used to infer where the drug may deposit in the lung.

However, for this data to be useful, such testing must in conducted in conditions that match how the product is likely to be used in the real world, which is where the TPK-R will be useful according to Copley.

Dry powder inhalers (DPIs) must be tested at a flow rate that reflects what will happen as a patient inhales. The TPK, and now the TPK-R, make it straight forward to determine what that flow rate should be, and to apply the right flow rate during testing​.”

The firm – which claims it has already sold 20 of the new TPK-R systems – will continue to supply both models of the testing technology and expects demand to be split 50/50 “in the fullness of time, as more users prefer the convenience of the arrangement as they move towards using the NGI.

Key customers will be those using the NGI to innovate new DPI technology and increasingly generic manufacturers looking to replicate the performance of DPIs initially tested with the NGI​.”

Related topics: Processing, QA/QC, Delivery technologies

Related news

Show more

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us


View more